Pre-specified 5-year analysis of a phase 3 RCT in 568 patients with nasopharyngeal carcinoma: medial retropharyngeal node-sparing radiotherapy gave similar local relapse-free survival to standard radiotherapy (89.2% vs 90.6%; HR 1.03), with less dysphagia (22% vs 32%).
RCTn = 568
Wang et al. Medial retropharyngeal nodal region sparing radiotherapy in nasopharyngeal carcinoma: five year analysis of open label, non-inferiority, multicentre, randomised phase 3 trial